Clinical studies were performed with a recombinant mutant adenovirus with an E1B 55-kDa deletion, dl1520, to assess its toxicity and efficacy in patients with irresectable primary and secondary liver tumors. A phase I study showed that dl1520 was well tolerated when administered directly intratumora...
Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.
No comments yet
Be the first to share your thoughts!